LXRX - Lexicon Pharmaceuticals, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
The Woodlands,
United States
Type: Equity
LXRX price evolution
LXRX
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $22.46 | $21.12 | $102.27 | $26 |
| Short term investments | $147.56 | $197.31 | $154.47 | $79.94 |
| Net receivables | $1.01 | $0.32 | $0.69 | $0.26 |
| Inventory | $0.38 | $0.34 | $0.17 | |
| Total current assets | $176.55 | $223.37 | $263.72 | $109.55 |
| Long term investments | ||||
| Property, plant & equipment | $7.51 | $7.82 | $8.46 | $8.63 |
| Goodwill & intangible assets | $44.54 | $44.54 | $44.54 | $44.54 |
| Total noncurrent assets | $52.88 | $53.11 | $53 | $53.17 |
| Total investments | $147.56 | $197.31 | $154.47 | $79.94 |
| Total assets | $229.43 | $276.48 | $316.72 | $162.72 |
| Current liabilities | ||||
| Accounts payable | $14.39 | $12.04 | $10.5 | $10.31 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $31.55 | $32.26 | $26.11 | $20.37 |
| Long term debt | $104.77 | $104.71 | $104.25 | $54.3 |
| Total noncurrent liabilities | $104.77 | $104.71 | $104.25 | $54.3 |
| Total debt | $104.77 | $104.71 | $104.25 | $54.3 |
| Total liabilities | $136.32 | $136.97 | $130.36 | $74.67 |
| Shareholders' equity | ||||
| Retained earnings | -$1766.84 | -$1717.08 | -$1666.56 | -$1621.65 |
| Other shareholder equity | $0.03 | -$0.11 | -$0.1 | -$0.16 |
| Total shareholder equity | $93.11 | $139.51 | $186.36 | $88.05 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $22.46 | $46.34 | $64.06 | $126.26 |
| Short term investments | $147.56 | $92.01 | $22.68 | $26.01 |
| Net receivables | $1.01 | $0.03 | $0.01 | $0.4 |
| Inventory | $0.38 | |||
| Total current assets | $176.55 | $140.87 | $88.92 | $157.72 |
| Long term investments | ||||
| Property, plant & equipment | $7.51 | $4.37 | $1.18 | $0.29 |
| Goodwill & intangible assets | $44.54 | $44.54 | $44.54 | $44.54 |
| Total noncurrent assets | $52.88 | $53.43 | $47.99 | $46.07 |
| Total investments | $147.56 | $92.01 | $22.68 | $26.01 |
| Total assets | $229.43 | $194.3 | $136.91 | $203.79 |
| Current liabilities | ||||
| Accounts payable | $14.39 | $10.39 | $9.15 | $5.47 |
| Deferred revenue | ||||
| Short long term debt | $11.65 | |||
| Total current liabilities | $31.55 | $23.17 | $22.12 | $46.81 |
| Long term debt | $104.77 | $48.58 | ||
| Total noncurrent liabilities | $104.77 | $54 | $1.19 | $0.61 |
| Total debt | $104.77 | $54 | $11.65 | |
| Total liabilities | $136.32 | $77.17 | $23.31 | $47.42 |
| Shareholders' equity | ||||
| Retained earnings | -$1766.84 | -$1589.72 | -$1487.78 | -$1400.02 |
| Other shareholder equity | $0.03 | -$0.43 | -$0.01 | -$0.01 |
| Total shareholder equity | $93.11 | $117.12 | $113.59 | $156.37 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.7 | $0.16 | $0.32 | $0.02 |
| Cost of revenue | $0.07 | $0.01 | $0.01 | |
| Gross Profit | $0.63 | $0.15 | $0.31 | $0.02 |
| Operating activities | ||||
| Research & development | $14.76 | $17.56 | $14.54 | $12.03 |
| Selling, general & administrative | $32.61 | $32.23 | $30.01 | $19.14 |
| Total operating expenses | $47.37 | $49.79 | $44.55 | $31.17 |
| Operating income | -$46.74 | -$49.63 | -$44.24 | -$31.14 |
| Income from continuing operations | ||||
| EBIT | -$44.34 | -$46.63 | -$42.94 | -$30.11 |
| Income tax expense | ||||
| Interest expense | $5.42 | $3.9 | $1.96 | $1.82 |
| Net income | ||||
| Net income | -$49.76 | -$50.52 | -$44.9 | -$31.93 |
| Income (for common shares) | -$49.76 | -$50.52 | -$44.9 | -$31.93 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $1.2 | $0.14 | $0.3 | $24 |
| Cost of revenue | $0.09 | $1.93 | ||
| Gross Profit | $1.12 | $0.14 | $0.3 | $22.07 |
| Operating activities | ||||
| Research & development | $58.89 | $52.82 | $55.05 | $153.62 |
| Selling, general & administrative | $113.98 | $48.08 | $32.34 | $47.23 |
| Total operating expenses | $172.87 | $100.9 | $87.39 | $69.87 |
| Operating income | -$171.75 | -$100.76 | -$87.09 | -$47.8 |
| Income from continuing operations | ||||
| EBIT | -$164.02 | -$99.16 | -$86.96 | -$44.03 |
| Income tax expense | ||||
| Interest expense | $13.1 | $2.78 | $0.8 | $14.54 |
| Net income | ||||
| Net income | -$177.12 | -$101.94 | -$87.76 | -$58.57 |
| Income (for common shares) | -$177.12 | -$101.94 | -$87.76 | -$58.57 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | -$49.76 | -$50.52 | -$44.9 | -$31.93 |
| Operating activities | ||||
| Depreciation | $0.15 | $0.15 | $0.14 | $0.11 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $3.21 | $3.9 | $3.81 | $3.42 |
| Total cash flows from operations | -$50.55 | -$41.62 | -$38.12 | -$31.61 |
| Investing activities | ||||
| Capital expenditures | -$0.08 | -$0.14 | -$0.25 | |
| Investments | $51.9 | -$39.24 | -$74.47 | $12.34 |
| Total cash flows from investing | $51.9 | -$39.33 | -$74.61 | $12.09 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | -$0.21 | $139.03 | -$0.82 | |
| Net borrowings | -$0 | $0 | $49.96 | |
| Total cash flows from financing | -$0 | -$0.21 | $189 | -$0.82 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $1.35 | -$81.16 | $76.27 | -$20.34 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$177.12 | -$101.94 | -$87.76 | -$58.57 |
| Operating activities | ||||
| Depreciation | $0.55 | $0.43 | $0.29 | $2.93 |
| Business acquisitions & disposals | $160.38 | |||
| Stock-based compensation | $14.34 | $11.52 | $10.58 | $13.27 |
| Total cash flows from operations | -$161.9 | -$88.85 | -$87.02 | -$142.97 |
| Investing activities | ||||
| Capital expenditures | -$0.47 | -$1.33 | -$1.22 | $10.93 |
| Investments | -$49.47 | -$69.75 | $3.33 | $209.44 |
| Total cash flows from investing | -$49.94 | -$71.08 | $2.11 | $380.76 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $138 | $93.34 | $34.41 | $68.94 |
| Net borrowings | $49.96 | $48.87 | -$11.7 | -$216.58 |
| Total cash flows from financing | $187.96 | $142.21 | $22.71 | -$147.64 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$23.88 | -$17.72 | -$62.2 | $90.15 |
News
Fundamentals
| Market cap | $418.82M |
|---|---|
| Enterprise value | $501.13M |
| Shares outstanding | 244.92M |
| Revenue | $1.21M |
|---|---|
| EBITDA | -$163.46M |
| EBIT | -$164.02M |
| Net Income | -$177.12M |
| Revenue Q/Q | 2.41K% |
| Revenue Y/Y | 766.91% |
| P/E ratio | -2.36 |
|---|---|
| EV/Sales | 415.87 |
| EV/EBITDA | -3.07 |
| EV/EBIT | -3.06 |
| P/S ratio | 347.57 |
| P/B ratio | 4.50 |
| Book/Share | 0.38 |
| Cash/Share | 0.09 |
| EPS | -$0.72 |
|---|---|
| ROA | -71.90% |
| ROE | -139.73% |
| Debt/Equity | 1.46 |
|---|---|
| Net debt/EBITDA | -0.70 |
| Current ratio | 5.60 |
| Quick ratio | 5.58 |